WO2003068801A3 - Antibody variants with faster antigen association rates - Google Patents

Antibody variants with faster antigen association rates Download PDF

Info

Publication number
WO2003068801A3
WO2003068801A3 PCT/US2003/004184 US0304184W WO03068801A3 WO 2003068801 A3 WO2003068801 A3 WO 2003068801A3 US 0304184 W US0304184 W US 0304184W WO 03068801 A3 WO03068801 A3 WO 03068801A3
Authority
WO
WIPO (PCT)
Prior art keywords
antibody variants
association rates
antigen association
faster
faster antigen
Prior art date
Application number
PCT/US2003/004184
Other languages
French (fr)
Other versions
WO2003068801A2 (en
Inventor
Henry B Lowman
Jonathan S Marvin
Original Assignee
Genentech Inc
Henry B Lowman
Jonathan S Marvin
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc, Henry B Lowman, Jonathan S Marvin filed Critical Genentech Inc
Priority to JP2003567927A priority Critical patent/JP2006506943A/en
Priority to BR0307548-6A priority patent/BR0307548A/en
Priority to AU2003216250A priority patent/AU2003216250A1/en
Priority to CA002472922A priority patent/CA2472922A1/en
Priority to EP03739759A priority patent/EP1573002A4/en
Priority to KR10-2004-7012316A priority patent/KR20040082421A/en
Priority to MXPA04007583A priority patent/MXPA04007583A/en
Publication of WO2003068801A2 publication Critical patent/WO2003068801A2/en
Publication of WO2003068801A3 publication Critical patent/WO2003068801A3/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55Fab or Fab'
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565Complementarity determining region [CDR]

Abstract

Antibody variants with faster antigen association rates are disclosed. The antibody variants have one or more amino acid alteration(s) in or adjacent to at least one hypervariable region thereof which increase charge complementarity between the antibody variant and an antigen to which it binds.
PCT/US2003/004184 2002-02-11 2003-02-11 Antibody variants with faster antigen association rates WO2003068801A2 (en)

Priority Applications (7)

Application Number Priority Date Filing Date Title
JP2003567927A JP2006506943A (en) 2002-02-11 2003-02-11 Antibody variants with high antigen binding rate
BR0307548-6A BR0307548A (en) 2002-02-11 2003-02-11 Method of producing an antibody variant, antibody variant, composition, isolated nucleic acid, vector, host cell, process for producing an antibody variant, and method of determining the antigen association coefficient of an antibody
AU2003216250A AU2003216250A1 (en) 2002-02-11 2003-02-11 Antibody variants with faster antigen association rates
CA002472922A CA2472922A1 (en) 2002-02-11 2003-02-11 Antibody variants with faster antigen association rates
EP03739759A EP1573002A4 (en) 2002-02-11 2003-02-11 Antibody variants with faster antigen association rates
KR10-2004-7012316A KR20040082421A (en) 2002-02-11 2003-02-11 Antibody Variants with Faster Antigen Association Rates
MXPA04007583A MXPA04007583A (en) 2002-02-11 2003-02-11 Antibody variants with faster antigen association rates.

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US35589502P 2002-02-11 2002-02-11
US60/355,895 2002-02-11
US40968502P 2002-09-10 2002-09-10
US60/409,685 2002-09-10

Publications (2)

Publication Number Publication Date
WO2003068801A2 WO2003068801A2 (en) 2003-08-21
WO2003068801A3 true WO2003068801A3 (en) 2005-06-30

Family

ID=27737510

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2003/004184 WO2003068801A2 (en) 2002-02-11 2003-02-11 Antibody variants with faster antigen association rates

Country Status (9)

Country Link
US (4) US20030224397A1 (en)
EP (1) EP1573002A4 (en)
JP (1) JP2006506943A (en)
KR (1) KR20040082421A (en)
AU (1) AU2003216250A1 (en)
BR (1) BR0307548A (en)
CA (1) CA2472922A1 (en)
MX (1) MXPA04007583A (en)
WO (1) WO2003068801A2 (en)

Families Citing this family (112)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7317091B2 (en) 2002-03-01 2008-01-08 Xencor, Inc. Optimized Fc variants
US8188231B2 (en) 2002-09-27 2012-05-29 Xencor, Inc. Optimized FC variants
US7662925B2 (en) 2002-03-01 2010-02-16 Xencor, Inc. Optimized Fc variants and methods for their generation
US20040132101A1 (en) 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
SI1501856T1 (en) 2002-04-10 2013-04-30 Genentech, Inc. Anti-her2 antibody variants
US20060235208A1 (en) * 2002-09-27 2006-10-19 Xencor, Inc. Fc variants with optimized properties
US8388955B2 (en) * 2003-03-03 2013-03-05 Xencor, Inc. Fc variants
US8084582B2 (en) 2003-03-03 2011-12-27 Xencor, Inc. Optimized anti-CD20 monoclonal antibodies having Fc variants
US20090010920A1 (en) 2003-03-03 2009-01-08 Xencor, Inc. Fc Variants Having Decreased Affinity for FcyRIIb
US9051373B2 (en) 2003-05-02 2015-06-09 Xencor, Inc. Optimized Fc variants
CN1802388B (en) * 2003-05-09 2011-01-05 杜克大学 CD20-specific antibodies and methods of employing same
US8597911B2 (en) * 2003-06-11 2013-12-03 Chugai Seiyaku Kabushiki Kaisha Process for producing antibodies
KR20120090094A (en) * 2003-06-13 2012-08-16 바이오겐 아이덱 엠에이 인코포레이티드 Aglycosyl anti-cd154(cd-40 ligand) antibodies and uses thereof
US8101720B2 (en) 2004-10-21 2012-01-24 Xencor, Inc. Immunoglobulin insertions, deletions and substitutions
US9714282B2 (en) 2003-09-26 2017-07-25 Xencor, Inc. Optimized Fc variants and methods for their generation
CA2561264A1 (en) 2004-03-24 2005-10-06 Xencor, Inc. Immunoglobulin variants outside the fc region
US20050227289A1 (en) * 2004-04-09 2005-10-13 Reilly Edward B Antibodies to erythropoietin receptor and uses thereof
US20060018902A1 (en) * 2004-04-09 2006-01-26 Reilly Edward B Antibodies to erythropoietin receptor and uses thereof
US20150010550A1 (en) 2004-07-15 2015-01-08 Xencor, Inc. OPTIMIZED Fc VARIANTS
JP5102028B2 (en) 2004-07-26 2012-12-19 バイオジェン・アイデック・エムエイ・インコーポレイテッド Anti-CD154 antibody
EP2325207B1 (en) 2004-11-12 2017-03-15 Xencor, Inc. FC variants with altered binding to FCRN
US8802820B2 (en) 2004-11-12 2014-08-12 Xencor, Inc. Fc variants with altered binding to FcRn
US8546543B2 (en) 2004-11-12 2013-10-01 Xencor, Inc. Fc variants that extend antibody half-life
US8367805B2 (en) 2004-11-12 2013-02-05 Xencor, Inc. Fc variants with altered binding to FcRn
CA2600929A1 (en) * 2005-03-04 2006-09-14 Biogen Idec Ma Inc. Methods of humanizing immunoglobulin variable regions through rational modification of complementarity determining residues
CA2603408C (en) 2005-03-31 2018-08-21 Chugai Seiyaku Kabushiki Kaisha Methods for producing polypeptides by regulating polypeptide association
US20100261288A1 (en) 2005-06-13 2010-10-14 Fortebio, Inc. Tip tray assembly for optical sensors
EP1931709B1 (en) 2005-10-03 2016-12-07 Xencor, Inc. Fc variants with optimized fc receptor binding properties
JP4860703B2 (en) 2005-10-06 2012-01-25 ゼンコー・インコーポレイテッド Optimized anti-CD30 antibody
US8128933B2 (en) 2005-11-23 2012-03-06 Acceleron Pharma, Inc. Method of promoting bone growth by an anti-activin B antibody
KR101557375B1 (en) 2005-11-23 2015-10-08 악셀레론 파마 인코포레이티드 Activin-actrπa antagonists and uses for promoting bone growth
US20070161042A1 (en) * 2006-01-11 2007-07-12 Fortebio, Inc. Methods for characterizing molecular interactions
NZ567888A (en) * 2006-03-23 2010-08-27 Bioarctic Neuroscience Ab Improved protofibril selective antibodies and the use thereof
ES2654040T3 (en) * 2006-03-31 2018-02-12 Chugai Seiyaku Kabushiki Kaisha Antibody modification method for the purification of bispecific antibodies
US11046784B2 (en) * 2006-03-31 2021-06-29 Chugai Seiyaku Kabushiki Kaisha Methods for controlling blood pharmacokinetics of antibodies
US8524867B2 (en) 2006-08-14 2013-09-03 Xencor, Inc. Optimized antibodies that target CD19
US20100093106A1 (en) * 2006-09-14 2010-04-15 Fortebio, Inc. Amine-Reactive Biosensor
CA2660795C (en) 2006-09-18 2014-11-18 Xencor, Inc. Optimized antibodies that target hm1.24
US20100111963A1 (en) * 2006-11-10 2010-05-06 Genentech, Inc. Method for treating age-related macular degeneration
US8895016B2 (en) 2006-12-18 2014-11-25 Acceleron Pharma, Inc. Antagonists of activin-actriia and uses for increasing red blood cell levels
EP2111229B1 (en) 2007-02-01 2013-04-10 Acceleron Pharma, Inc. Pharmaceutical compositions comprising Activin-ActRIIA antagonists for use in preventing or treating breast cancer metastasis or breast cancer related bone loss
TW201803890A (en) 2007-02-02 2018-02-01 艾瑟勒朗法瑪公司 Variants derived from ActRIIB and uses therefor
KR20160129095A (en) 2007-02-09 2016-11-08 악셀레론 파마 인코포레이티드 Activin-actriia antagonists and uses for promoting bone growth in cancer patients
CN101861161B (en) 2007-09-18 2017-04-19 阿塞勒隆制药公司 Activin-ACTRIIA antagonists and uses for decreasing or inhibiting FSH secretion
EP3415529B1 (en) * 2007-09-26 2020-11-04 Chugai Seiyaku Kabushiki Kaisha Modified antibody constant region
ES2595638T3 (en) * 2007-09-26 2017-01-02 Chugai Seiyaku Kabushiki Kaisha Method to modify the isoelectric point of an antibody by replacing amino acids in a CDR
TWI472339B (en) 2008-01-30 2015-02-11 Genentech Inc Composition comprising antibody that binds to domain ii of her2 and acidic variants thereof
CN103251948A (en) 2008-04-11 2013-08-21 中外制药株式会社 Antigen-binding molecule capable of binding to two or more antigen molecules repeatedly
AU2009241589B2 (en) 2008-04-29 2013-10-10 Abbvie Inc. Dual variable domain immunoglobulins and uses thereof
WO2009135861A2 (en) * 2008-05-07 2009-11-12 Novo Nordisk A/S Humanized antibodies against human interferon-alpha
CN102112494A (en) 2008-06-03 2011-06-29 雅培制药有限公司 Dual variable domain immunoglobulins and uses thereof
UY31862A (en) 2008-06-03 2010-01-05 Abbott Lab IMMUNOGLOBULIN WITH DUAL VARIABLE DOMAIN AND USES OF THE SAME
JP5674654B2 (en) 2008-07-08 2015-02-25 アッヴィ・インコーポレイテッド Prostaglandin E2 double variable domain immunoglobulin and use thereof
US8216997B2 (en) 2008-08-14 2012-07-10 Acceleron Pharma, Inc. Methods for increasing red blood cell levels and treating anemia using a combination of GDF traps and erythropoietin receptor activators
PT3494986T (en) 2008-08-14 2020-07-14 Acceleron Pharma Inc Gdf traps for use to treat anemia
TWI440469B (en) 2008-09-26 2014-06-11 Chugai Pharmaceutical Co Ltd Improved antibody molecules
WO2010051502A2 (en) * 2008-10-31 2010-05-06 Biogen Idec Ma Inc. Light targeting molecules and uses thereof
JP5787446B2 (en) 2009-03-19 2015-09-30 中外製薬株式会社 Antibody constant region variants
JP5717624B2 (en) 2009-03-19 2015-05-13 中外製薬株式会社 Antibody constant region variants
MX2011010908A (en) 2009-04-16 2012-02-21 Abbott Biotherapeutics Corp Anti-tnf-î± antibodies and their uses.
WO2010129532A2 (en) * 2009-05-05 2010-11-11 Trustees Of Boston University Method and device for rapid detection of bacterial antibiotic resistance/susceptibility
US8178488B2 (en) 2009-06-08 2012-05-15 Acceleron Pharma, Inc. Methods for increasing thermogenic adipocytes
KR20190090049A (en) 2009-06-12 2019-07-31 악셀레론 파마 인코포레이티드 TRUNCATED ActRIIB-FC FUSION PROTEINS
US9079953B2 (en) 2009-06-17 2015-07-14 Abbvie Biotherapeutics Inc. Anti-VEGF antibodies and their uses
WO2011028811A2 (en) 2009-09-01 2011-03-10 Abbott Laboratories Dual variable domain immunoglobulins and uses thereof
WO2011028952A1 (en) 2009-09-02 2011-03-10 Xencor, Inc. Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens
EP2481752B1 (en) 2009-09-24 2016-11-09 Chugai Seiyaku Kabushiki Kaisha Modified antibody constant regions
CA2775959A1 (en) 2009-10-15 2011-04-21 Abbott Laboratories Dual variable domain immunoglobulins and uses thereof
UY32979A (en) 2009-10-28 2011-02-28 Abbott Lab IMMUNOGLOBULINS WITH DUAL VARIABLE DOMAIN AND USES OF THE SAME
CA2781152A1 (en) 2009-11-17 2011-05-26 Acceleron Pharma Inc. Actriib proteins and variants and uses therefore relating to utrophin induction for muscular dystrophy therapy
BR112012012983A2 (en) 2009-12-04 2020-09-15 Genentech Inc method of synthesizing a multispecific antibody, method of synthesizing a panel of multispecific antibodies, method of synthesizing an antibody analog, method of synthesizing a panel of antibody analogs and compositions
ES2594893T3 (en) 2009-12-16 2016-12-23 Abbvie Biotherapeutics Inc. Anti HER2 antibodies and their uses
WO2011091078A2 (en) 2010-01-19 2011-07-28 Xencor, Inc. Antibody fc variants with enhanced complement activity
EP2543730B1 (en) 2010-03-04 2018-10-31 Chugai Seiyaku Kabushiki Kaisha Antibody constant region variant
FR2958753B1 (en) * 2010-04-13 2018-03-16 Institut De Recherche Pour Le Developpement (Ird) ANTIGENIC CONSTRUCTION AND ITS APPLICATIONS FOR THE DETECTION OF TRYPANOSOMOSES IN MAN AND ANIMALS
CA2797741A1 (en) * 2010-05-07 2011-11-10 F. Hoffmann-La Roche Ag Diagnostic method for the detection of cells ex vivo
AU2011285852B2 (en) 2010-08-03 2014-12-11 Abbvie Inc. Dual variable domain immunoglobulins and uses thereof
BR112013004581A2 (en) 2010-08-26 2017-06-27 Abbvie Inc dual variable domain immunoglobulins and their uses
CN103154741B (en) * 2010-09-17 2016-02-03 国立大学法人东北大学 Containing the decision method of antibody as the validity of the pharmaceuticals of composition
AU2011326586A1 (en) 2010-11-08 2013-05-30 Acceleron Pharma, Inc. ActRIIA binding agents and uses thereof
TWI452136B (en) 2010-11-17 2014-09-11 中外製藥股份有限公司 A multiple specific antigen-binding molecule that replaces the function of Factor VIII in blood coagulation
CN112812184A (en) 2011-02-25 2021-05-18 中外制药株式会社 Fc gamma RIIb specific Fc antibodies
WO2012133047A1 (en) * 2011-03-25 2012-10-04 コニカミノルタエムジー株式会社 Immunohistological staining method and method for determining effectiveness of antibody preparation using same
TW201817745A (en) 2011-09-30 2018-05-16 日商中外製藥股份有限公司 Therapeutic antigen-binding molecule with a FcRn-binding domain that promotes antigen clearance
EP3939996A1 (en) 2011-09-30 2022-01-19 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule promoting disappearance of antigens having plurality of biological activities
MX359775B (en) 2011-10-31 2018-10-10 Chugai Pharmaceutical Co Ltd Antigen-binding molecule having regulated conjugation between heavy-chain and light-chain.
MX2014008101A (en) 2011-12-30 2014-09-25 Abbvie Inc Dual variable domain immunoglobulins against il-13 and/or il-17.
US9777067B2 (en) 2012-09-27 2017-10-03 Massachusetts Institute Of Technology HER2- and VEGF-A-binding proteins with enhanced stability
TWI601745B (en) 2012-11-01 2017-10-11 艾伯維有限公司 Anti-vegf/dll4 dual variable domain immunoglobulins and uses thereof
RU2018145985A (en) 2012-11-02 2019-02-18 Селджин Корпорейшн ACTIVIN-ACTRII ANTAGONISTS AND THEIR APPLICATION FOR TREATMENT OF BONE TISSUE DISORDERS AND OTHER DISORDERS
UY35148A (en) 2012-11-21 2014-05-30 Amgen Inc HETERODIMERIC IMMUNOGLOBULINS
US20140154255A1 (en) 2012-11-30 2014-06-05 Abbvie Biotherapeutics Inc. Anti-vegf antibodies and their uses
CA2904448A1 (en) 2013-03-15 2014-09-18 Tariq Ghayur Dual specific binding proteins directed against il-1.beta. and/or il-17
CA2925256C (en) 2013-09-27 2023-08-15 Chugai Seiyaku Kabushiki Kaisha Method for producing polypeptide heteromultimer
US9850298B2 (en) 2014-06-13 2017-12-26 Acceleron Pharma Inc. Methods for treating ulcers in thalassemia syndrome with an ActRIIB polypeptide
MA40764A (en) 2014-09-26 2017-08-01 Chugai Pharmaceutical Co Ltd THERAPEUTIC AGENT INDUCING CYTOTOXICITY
MA41052A (en) 2014-10-09 2017-08-15 Celgene Corp TREATMENT OF CARDIOVASCULAR DISEASE USING ACTRII LIGAND TRAPS
TWI730949B (en) 2014-12-03 2021-06-21 美商西建公司 Activin-actrii antagonists and uses for treating anemia
WO2016094881A2 (en) 2014-12-11 2016-06-16 Abbvie Inc. Lrp-8 binding proteins
RU2746356C2 (en) 2014-12-19 2021-04-12 Чугаи Сейяку Кабусики Кайся C5 antibodies and their application methods
CA2963760A1 (en) 2014-12-19 2016-06-23 Yoshinao Ruike Anti-myostatin antibodies, polypeptides containing variant fc regions, and methods of use
WO2016125495A1 (en) 2015-02-05 2016-08-11 Chugai Seiyaku Kabushiki Kaisha Antibodies comprising an ion concentration dependent antigen-binding domain, fc region variants, il-8-binding antibodies, and uses therof
CN107249637A (en) 2015-02-27 2017-10-13 中外制药株式会社 Composition for treating the relevant diseases of IL 6
JP7082484B2 (en) 2015-04-01 2022-06-08 中外製薬株式会社 Method for Producing Polypeptide Heterogeneous Multimer
TW201710286A (en) 2015-06-15 2017-03-16 艾伯維有限公司 Binding proteins against VEGF, PDGF, and/or their receptors
JP7141336B2 (en) 2015-12-25 2022-09-22 中外製薬株式会社 Anti-myostatin antibodies and methods of use
KR20180091918A (en) 2015-12-28 2018-08-16 추가이 세이야쿠 가부시키가이샤 A method for efficiently purifying the Fc region-containing polypeptide
CA3016424A1 (en) 2016-03-14 2017-09-21 Chugai Seiyaku Kabushiki Kaisha Cell injury inducing therapeutic drug for use in cancer therapy
SG11201808426XA (en) 2016-04-15 2018-10-30 Univ Pennsylvania Compositions for treatment of wet age-related macular degeneration
CN116251182A (en) 2016-08-05 2023-06-13 中外制药株式会社 Compositions for preventing or treating IL-8 related diseases
WO2018203545A1 (en) 2017-05-02 2018-11-08 国立研究開発法人国立精神・神経医療研究センター Method for predicting and evaluating therapeutic effect in diseases related to il-6 and neutrophils
TW202034958A (en) * 2018-10-30 2020-10-01 丹麥商珍美寶股份有限公司 Methods of treating cancer with a combination of an anti-vegf antibody and an anti-tissue factor antibody-drug conjugate

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6632926B1 (en) * 1998-11-18 2003-10-14 Genentech, Inc. Antibody variants

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US550362A (en) * 1895-11-26 crosby
IL85035A0 (en) * 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
CN101210051B (en) * 1997-04-07 2012-12-26 基因技术股份有限公司 Anti-VEGF antibodies
US6194551B1 (en) * 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
WO2001062931A2 (en) * 2000-02-25 2001-08-30 The Government Of The United States, As Represented By The Secretary Of The Department Of Health And Human Services ANTI-EGFRvIII SCFVS WITH IMPROVED CYTOTOXICITY AND YIELD, IMMUNOTOXINS BASED THEREON, AND METHODS OF USE THEREOF

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6632926B1 (en) * 1998-11-18 2003-10-14 Genentech, Inc. Antibody variants

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
FOGOLARI ET AL.: "Simulation of electrostatic effects in Fab-antigen complex formation", EUROPEAN JOURNAL OF BIOCHEMISTRY, vol. 267, 2000, pages 4861 - 4869, XP002986093 *
MULLER ET AL.: "VEGF and the Fab fragment of a humanized neutralizing antibody: crystal structure of the complex at 2.4.A resolution and mutational analysis of the interface", STRUCTURE, vol. 6, no. 9, 15 September 1998 (1998-09-15), pages 1153 - 1167, XP002986094 *
See also references of EP1573002A4 *
SELZER ET AL.: "Rational design of faster associating and tighter binding protein complexes", NATURE STRUCTURAL BIOLOGY, vol. 7, no. 7, July 2000 (2000-07-01), pages 537 - 541, XP008047548 *

Also Published As

Publication number Publication date
AU2003216250A1 (en) 2003-09-04
EP1573002A2 (en) 2005-09-14
JP2006506943A (en) 2006-03-02
US20100291072A1 (en) 2010-11-18
KR20040082421A (en) 2004-09-24
EP1573002A4 (en) 2008-07-16
US20080299115A1 (en) 2008-12-04
BR0307548A (en) 2006-01-17
WO2003068801A2 (en) 2003-08-21
US20070037255A1 (en) 2007-02-15
MXPA04007583A (en) 2005-04-25
CA2472922A1 (en) 2003-08-21
US20030224397A1 (en) 2003-12-04

Similar Documents

Publication Publication Date Title
WO2003068801A3 (en) Antibody variants with faster antigen association rates
HRP20151252T4 (en) Modified antibody fab fragments
IL172871A (en) Isolated human antibody or antigen-binding fragment thereof, an immunoconjugate, a single chain antibody molecule and a polypeptide comprising the same and uses thereof
HK1081647A1 (en) N-11 truncated amyloid-beta monoclonal antibodies, compositions, methods and uses
WO2006130458A3 (en) Antibodies directed to cd20 and uses thereof
IN2009KN02655A (en)
WO2006039258A3 (en) Human antibodies against parathyroid hormone
WO2004108889A3 (en) Hybrid antibodies
WO2005016111A3 (en) Antibodies directed to parathyroid hormone (PTH) and uses thereof
WO2007120693A3 (en) Targeted binding agents directed to upar and uses thereof
AU2003265883A1 (en) Monoclonal antibodies and complementarity-determining regions binding to ebola glycoprotein
WO2008079995A3 (en) Conjugate of natriuretic peptide and antibody constant region
WO2003048321A3 (en) Hybrid antibodies
WO2004050683A8 (en) Antibodies directed to tumor necrosis factor and uses thereof
WO2006081139A3 (en) Antibodies against interleukin-1 beta
WO2005068503A3 (en) M-csf-specific monoclonal antibody and uses thereof
IL176940A (en) Isolated antibody or an antigen binding fragment thereof that binds ige
WO2008112004A3 (en) ANTIBODIES DIRECTED TO αVβ6 AND USES THEREOF
EP1607404A4 (en) Monoclonal antibody and hybridoma producing the same
TNSN06087A1 (en) Therapeutic binding molecules
IL172242A0 (en) Antibodies specific for cancer associated antigen sm5-1 and uses thereof
EP1491555A4 (en) Anti-human hepatoma monoclonal antibody hab18 light/heavy chain variable region gene, and use thereof
WO2005023201A3 (en) Methods for treating rheumatoid arthritis
AU2002359495A1 (en) Anti-tnf antibodies, compositions, methods and uses
AU2003225976A1 (en) Anti-tnf antibodies, compositions, methods and uses

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2472922

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2004/05725

Country of ref document: ZA

Ref document number: 200405725

Country of ref document: ZA

WWE Wipo information: entry into national phase

Ref document number: 163109

Country of ref document: IL

Ref document number: 2003216250

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2003739759

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 534280

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: PA/a/2004/007583

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 1020047012316

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 2003567927

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 20038081253

Country of ref document: CN

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWP Wipo information: published in national office

Ref document number: 2003739759

Country of ref document: EP

ENP Entry into the national phase

Ref document number: PI0307548

Country of ref document: BR